Neuphoria Therapeutics Inc. (NEUP)
$3.76-$0.01 (-0.27%) Today
David Ian Wilson - Director
Spyros Papapetropoulos - OfficerDavid Ian Wilson - DirectorNeuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
No Form 4 activity for NEUP in the last 90 days.
11 Form 4 filings on record, the earliest from Apr 16, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Ian Wilson - Director | Grant or award | Restricted Stock Units | 8,537 | $0.00 | - | |
| Peter Miles Winston Davies - Director | Grant or award | Restricted Stock Units | 8,537 | $0.00 | - | |
| Alan Fisher - Director | Grant or award | Restricted Stock Units | 17,073 | $0.00 | - | |
| Jane Ryan - Director | Grant or award | Restricted Stock Units | 8,537 | $0.00 | - | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.00001 par value per share | 639,110 | $5.14 | $3.28M | |
| Spyros Papapetropoulos - Officer | Grant or award | Employee Stock Option (Right-to- Buy) | 34,559 | $8.27 | $286K | |
| Jane Ryan - Director | Grant or award | Restricted Stock Units | 6,783 | $0.00 | - | |
| David Ian Wilson - Director | Grant or award | Restricted Stock Units | 6,783 | $0.00 | - | |
| Spyros Papapetropoulos - Officer | Grant or award | Employee Stock Option (Right-to-Buy) | 27,000 | $5.16 | $139K | |
| Alan Fisher - Director | Grant or award | Restricted Stock Units | 13,566 | $0.00 | - | |
| Peter Miles Winston Davies - Director | Grant or award | Restricted Stock Units | 6,783 | $0.00 | - |
Neuphoria Therapeutics Inc. (NEUP) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-01-21. The full record for NEUP runs to 11 Form 4 filings, the earliest from 2025-04-16. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of NEUP were filed in the last 90 days. 1 purchase is on record for this company.
No insider sales of NEUP were filed in the last 90 days.
This page tracks NEUP Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add NEUP to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
